Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification by Estella.

Slides:

Advertisements

Similar presentations

ICCS e-Newsletter CSI Winter 2013

Advertisements

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Society for Hematopathology/European Association for Haematopathology 2013 Case Number 208 Erika Moore, MD; Darshan Roy, MD; Patti Cohen, MD; Adam Bagg,

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

How I treat prolymphocytic leukemia

eCSI case 2 – November 2016 Jyotinder Nain Punia, MD

Clinical history 30-years-old female

Clinically useful prognostic factors in acute myeloid leukemia

Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.

Figure 2 Percentage of CD19+/CD34+ cells with decreased CD81 median fluorescence intensity (MFI;

The formation of an aberrant PAX5 transcript in a patient with mixed phenotype acute leukemia harboring der(9)t(7;9)(q11.2;p13) Jun Amaki, Hiromichi.

Early T-Cell Precursor ALL in 5 Year Old Female

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

How I treat LGL leukemia

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Flow cytometric immunophenotyping for hematologic neoplasms

by Laurence J. N. Cooper, Kevin M. Shannon, Michael R

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.

by Udomsak Bunworasate, Hilal Arnouk, Hans Minderman, Kieran L

by Venetia Bigley, Laura E. Spence, and Matthew Collin

CD25 expression is associated with unfavorable clinical outcome.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,

Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia:

How I treat extramedullary acute myeloid leukemia

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

by Karthik A. Ganapathi, Danielle M. Townsley, Amy P. Hsu, Diane C

Fusion genes in cord blood

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma by Marion Lambert, Monique.

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

A Strong Expression of CD44-6v Correlates With Shorter Survival of Patients With Acute Myeloid Leukemia by S. Legras, U. Günthert, R. Stauder, F. Curt,

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital by Jeffrey E. Rubnitz, Mihaela Onciu, Stanley Pounds,

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study by Daniel J. DeAngelo, Wendy.

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis by Julie Støve Bødker, Rasmus Froberg Brøndum,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

by John Anastasi, Rizwan Moinuddin, and Christopher Daugherty

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia Reinhold Munker, Ruta Brazauskas, Hai Lin Wang, Marcos.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

d a c b CD8 CD3 CD4 CD62L HLA-DR CD57 10% 85% 11% 76% 19% 60% 36% 66%

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

Phenotype of rTT.C-specific plasma blasts.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR by Duncan Murray, Jack Luke McMurray,

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia by Ross Kinstrie, Dimitris Karamitros, Nicolas Goardon, Heather Morrison,

HOXB6 overexpression results in delayed AML

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Alteration calling accuracy and concordance with reference platforms.

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib by Chung H. Kok, David T.

Outline of antibody groups used in panels for identification of AML-aberrant immunophenotypes (both for LAIP and “different-from-normal” approaches) and.

Overall survival of systemic mastocytosis patients.

Two major molecular subgroups within PTCL-NOS with biological and overall survival differences. Two major molecular subgroups within PTCL-NOS with biological.

Correlation of TAN phenotypes and TIL effector function.

Presentation transcript:

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification by Estella Matutes, Winfried F. Pickl, Mars van't Veer, Ricardo Morilla, John Swansbury, Herbert Strobl, Andishe Attarbaschi, Georg Hopfinger, Sue Ashley, Marie Christine Bene, Anna Porwit, Alberto Orfao, Petr Lemez, Richard Schabath, and Wolf-Dieter Ludwig Blood Volume 117(11):3163-3171 March 17, 2011 ©2011 by American Society of Hematology

May-Grunwald-Giemsa–stained BM smear showing a mixed-cell population of large and small blasts. Estella Matutes et al. Blood 2011;117:3163-3171 ©2011 by American Society of Hematology

Dot plots with the blast population highlighted in blue (R1) and lymphocyte population in green (R2). Dot plots with the blast population highlighted in blue (R1) and lymphocyte population in green (R2). These dot plots demonstrate the expression of CD13 and CD33 and coexpression of MPO with cytCD3. Residual T lymphocytes are positive for cyt.CD3 but MPO-negative. CD19 and CD7 are negative. Estella Matutes et al. Blood 2011;117:3163-3171 ©2011 by American Society of Hematology

Dot plots with the blast population highlighted in red (R1) and lymphocyte population in green (R2). Dot plots with the blast population highlighted in red (R1) and lymphocyte population in green (R2). These dot plots demonstrate the expression of CD13 and coexpression of MPO with CD19. Other positive markers are CD34, CD79a, and TdT. CD7, CD15, and lysozyme are negative Estella Matutes et al. Blood 2011;117:3163-3171 ©2011 by American Society of Hematology

Infinicyte band representation. Infinicyte band representation. (A) Of merged files showing intracytoplasmic expression of CD3 and CD79a but negative MPO and (B) of merged files showing membrane expression of CD10, CD19, and CD7 with weak expression of CD34 and HLA-DR in the same case (B + T-lymphoid phenotype). There is lack of expression of CD117. Estella Matutes et al. Blood 2011;117:3163-3171 ©2011 by American Society of Hematology

Overall survival of MPAL patients. Overall survival of MPAL patients. (A) Overall survival for the whole MPAL series. (B-D) The median survival of patient groups established according to age (B), cytogenetics (C), and the type of induction therapy (D). Estella Matutes et al. Blood 2011;117:3163-3171 ©2011 by American Society of Hematology